Sees FY25 adjusted EBITDA loss $35M. Sees FY25 gross margin 64.5%. Sees FY25 operating expense $300M. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipRanks >> Read More on PRCT: Procept BioRobotics reports Q4 EPS (35c), consensus (35c) Is PRCT a Buy, Before Earnings? Spruce Point Capital says short Procept BioRobotics Morgan Stanley Sees Potential Growth in These 2 Surgical Robotic Stocks Disclaimer & DisclosureReport an Issue